ADVB · XBRL financial data
Advanced Biomed financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (ADVB's year ends in late June)
| In thousands of dollars | Jun 30, 2025 | †Jun 30, 2026 |
|---|---|---|
| Revenue | — | 128 |
| Research and development | 910 | — |
| General and administrative | 2,111 | 4,627 |
| Total operating expenses | 3,021 | 6,361 |
| Operating income (loss) | (1,086) | (6,234) |
| Interest income | 25 | — |
| Other income (expense) | (263) | (22) |
| Income tax expense (benefit) | — | (1) |
| Net income (loss) | (3,259) | 6,677 |
| Earnings per share, basic USD per share | (0.16) | 5.33 |
| Earnings per share, diluted USD per share | (0.16) | 5.33 |
| Weighted average shares, basic thousands of shares | 20,526 | 1,253 |
| Weighted average shares, diluted thousands of shares | 20,526 | 1,253 |
- † Share count changed about 1/13 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (ADVB's year ends in late June)
| In thousands of dollars | Jun 30, 2025 | †Jun 30, 2026 |
|---|---|---|
| Cash and cash equivalents | 2,904 | 386 |
| Prepaid and other current assets | 3,129 | 13,364 |
| Total current assets | 6,033 | 13,750 |
| Property and equipment, net | 331 | — |
| Right-of-use asset | 65 | — |
| Total assets | 6,512 | 13,751 |
| Accounts payable | 633 | — |
| Accrued liabilities | 448 | 232 |
| Total current liabilities | 2,889 | 1,474 |
| Lease liability, non-current | 6 | — |
| Total liabilities | 3,035 | 1,474 |
| Accumulated deficit | (19,233) | (12,556) |
| Total stockholders' equity | 3,478 | 12,277 |
| Total liabilities and equity | 6,512 | 13,751 |
| Common shares outstanding (cover page) thousands of shares | 21,640 | 1,652 |
- † Share count changed about 1/13 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (ADVB's year ends in late June)
| In thousands of dollars | Jun 30, 2025 | †Jun 30, 2026 |
|---|---|---|
| Net income (loss) | (3,259) | 6,677 |
| Stock-based compensation | — | 1,734 |
| Net cash from operating activities | (5,825) | (1,947) |
| Purchases of property and equipment | 32 | — |
| Net cash from investing activities | (32) | (2,506) |
| Proceeds from issuing common stock | 5,494 | 248 |
| Net cash from financing activities | 5,934 | 1,968 |
| Net change in cash | 296 | (2,518) |
- † Share count changed about 1/13 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Advanced Biomed | 386 | year only | (583)* | 1.7M | 0.7 quarters | 10-KJun 30, 2026 |
| Aclarion | 16,285 | 25 | (2,657)* | 2.9M | 6.1 quarters | 10-QJun 30, 2026 |
| BioNexus Gene Lab | 1,233 | 76 | (422)* | 2.9M | 2.9 quarters | 10-QJun 30, 2026 |
| Ludwig Enterprises | 18 | not reported | (153) | 167.2M | 1.3 quarters | 10-QMar 31, 2026 |
| CapForce | 144 | 50,000 | (618)* | 12.4M | 0.2 quarters | 10-QJun 30, 2026 |
| American Shared Hospital Services | 6,511 | 8,430 | 2,236* | 6.7M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.